Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 11, LifeSci Capital reiterated its Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) with a price target of $110 on the stock.
On December 8, Piper Sandler identified Soleno Therapeutics, Inc. (NASDAQ:SLNO) as one of several commercial-stage biotech companies expected to experience transformational growth in 2026. According to a research note following the firm’s three-day Healthcare Conference, discussions with management teams provided clearer insight into upcoming launches and possible approvals.
Piper Sandler expressed improved confidence in these companies, including Soleno Therapeutics, Inc. (NASDAQ:SLNO), and noted that these companies have a solid plan to commence or progress drug launches.
In other news, on January 5, Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced that results from a pivotal study of VYKAT XR were published in the Journal of Clinical Endocrinology and Metabolism (JCEM). The study was a key part of the Phase 3 clinical program, which established the efficacy and safety of the drug. It also supported the drug’s approval by the FDA as the first and only treatment for hyperphagia in people living with Prader-Willi syndrome.
Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a biopharmaceutical company focused on developing novel therapeutics for the treatment of rare diseases.
While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best US Penny Stocks to Buy and 10 Best New Penny Stocks to Invest In.
Disclosure: None. This article is originally published at Insider Monkey.
